Infliximab for peristomal pyoderma gangrenosum

British Journal of Dermatology

Volumn 148, Issue 4, 2003, Pages 813-816

  Mimouni, D ^a   Anhalt, G J ^a   Kouba, D J ^a   Nousari, H Carlos ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infliximab; Peristomal eruption; Pyoderma gangrenosum

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; HUMAN; NEPHROTOXICITY; OSTEOPOROSIS; PERISTOMAL PYODERMA GANGRENOSUM; PRIORITY JOURNAL; PROCTOCOLECTOMY; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PYODERMA GANGRENOSUM;

EID: 0038240008     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05294.x     Document Type: Article

References (23)

1. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
2. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
3. Olivieri I, Padula A, Ciancio G et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61: 375-6.
4. Tan MH, Gordon M, Lebwohl O et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-3.
5. Voigtlander C, Luftl M, Schuler G et al. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137: 1571-4.
6. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001; 68: 287-97.
7. Cuttino C. Pyoderma gangrenosum: an innovative wound care protocol. J Enterostomal Ther 1987; 14: 216-19.
8. Lyon CC, Smith AJ, Beck MH et al. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 2000; 42: 992-1002.
9. Nousari HC, Anhalt GJ. Immunosuppressive and immunomodulatory drugs. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds), 5th edn. New York: McGraw-Hill, 1999; 2853-68.
10. Lugering A, Schmidt M, Lugering N et al. lnfliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57.
11. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66.
12. Reinecker HC, Steffen M. Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
13. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
14. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001; 19: 617-35.
15. D'Haens G, van Deventer SJ, van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
16. Present DH, Rutgeerts P, Targan SR et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
17. Rutgeerts P, D'Haens G, Targan SR et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
18. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
19. Botros N, Pickover L, Das KM. Image of the month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 2000; 118: 654, 809.
20. Geyer AS, Anhalt GJ, Nousari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn's disease. Arch Dermatol 2000; 136: 459-60.
21. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-8.
22. Lankarani KB. Mortality associated with infliximab. J Clin Gastroenterol 2001; 33: 255-6.
23. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000; 95: 2395-6.